Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Reviewers Share CMC, GMP Challenges In Last Year's Rush To Approve New Therapies

Executive Summary

Inundated with high-priority applications last year, US FDA's CMC reviewers struggled with seemingly thrown-together review packages, moving-target manufacturing processes and not-on-the-same-page contract manufacturers.

You may also be interested in...



US FDA To Sponsors: Tell Us More About Your Drug Development Before We Meet

Requests for meetings with FDA staff about products in development should include pertinent details about pediatric study plans, human factors engineering plans and combination product information; new guidance documents on formal meetings under PDUFA VI and communications with IND sponsors operationalize user fee program commitments and will promote earlier, more thorough engagement, agency says.

FDA Achieves Historically Low Eight-Month Median Drug Review Time In 2017

Median review times for US agency's drug center were 10 months from 2011 to 2013, and 11 months from 2015 to 2016.

FDA Warning Letter Brings Another High-Flying Emergent CDMO Plant Down To Earth

Warning letter reveals agency found quality problems at Emergent BioSolutions’ Camden fill/finish plant during COVID-19 pandemic even as firm’s Bayview plant came under heightened scrutiny. Metal particulates appeared in vials as Camden plant and rest of Emergent’s CDMO network experienced sharp demand growth.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS122447

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel